Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial

Natalie Y.l. Ngoi, Chel Hun Choi, Junxian Zhu, Diana Lim, Tuan Zea Tan, Haoyang Sun, Valerie Heong, Samuel G.w. Ow, Wen Yee Chay, Hee Seung Kim, Yi Wan Lim, Siew Eng Lim, Geraldine Goss, Jeffrey C. Goh, Jae‐Weon Kim, Michael Friedländer, Bee Choo Tai, Kidong Kim, David S.p. TanClinical 2025 · DOI

Abstract

Durvalumab was well-tolerated but did not improve efficacy outcomes compared with chemotherapy in rOCCC.
BibTeX
@inproceedings{ngoi2025durvalumab,
  author = {Natalie Y.L. Ngoi and Chel Hun Choi and Junxian Zhu and Diana Lim and Tuan Zea Tan and Haoyang Sun and Valerie Heong and Samuel G.W. Ow and Wen Yee Chay and Hee Seung Kim and Yi Wan Lim and Siew Eng Lim and Geraldine Goss and Jeffrey C. Goh and Jae‐Weon Kim and Michael Friedländer and Bee Choo Tai and Kidong Kim and David S.P. Tan},
  title = {{Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1158/1078-0432.ccr-25-0201},
}

Loading related content...

Figure